Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials

OBJECTIVES: In the anifrolumab systemic lupus erythematosus (SLE) trial programme, there was one trial (TULIP-1) in which BILAG-based Composite Lupus Assessment (BICLA) responses favoured anifrolumab over placebo, but the SLE Responder Index (SRI(4)) treatment difference was not significant. We inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruce, Ian N, Furie, Richard A, Morand, Eric F, Manzi, Susan, Tanaka, Yoshiya, Kalunian, Kenneth C., Merrill, Joan T, Puzio, Patricia, Maho, Emmanuelle, Kleoudis, Christi, Albulescu, Marius, Hultquist, Micki, Tummala, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213793/
https://www.ncbi.nlm.nih.gov/pubmed/35580976
http://dx.doi.org/10.1136/annrheumdis-2021-221847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213793/
https://www.ncbi.nlm.nih.gov/pubmed/35580976
http://dx.doi.org/10.1136/annrheumdis-2021-221847

Ejemplares similares